Vitality Watch

Dossier pubmed trial late 04-nov-2026
Large or late-phase randomized human trial

Targeting Accelerated Aging in COPD: The AMICO (A Trial of Metformin In COpd) Trial Design.

Key claim: The phase III AMICO trial evaluates whether 36 months of metformin (850 mg twice daily) can act as a gerotherapeutic to slow lung function decline and reduce age-related comorbidities in COPD.

Abstract

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a disease of accelerated biological aging characterized by progressive lung function decline, emphysema progression and multiple age-related comorbidities. Current therapies improve symptoms and reduce exacerbations but have limited effects on disease progression. Metformin has demonstrated anti-aging properties through modulation of pathways involved in oxidative stress, inflammation, mitochondrial dysfunction and cellular senescence, making it a potential disease-modifying treatment in COPD. METHODS: AMICO (A Trial of Metformin In COPD) is an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled phase III trial conducted in. A total of 212 patients with clinically stable COPD, centrilobular emphysema on computed tomography, post-bronchodilator FEV40%-70% predicted and accelerated FEVdecline (>40 mL·year) will be randomized (1:1) to receive metformin (850 mg twice daily) or matching placebo for 36 months in addition to standard COPD treatment. Assessments include pulmonary function, chest computed tomography, exercise capacity, health status, muscle strength, body composition, age associated comorbidities development and aging-related biomarkers.The primary endpoint is the annual rate of FEVdecline over 36 months. Secondary endpoints include emphysema progression, changes in diffusing capacity, COPD Assessment Test score, 6-minute walk distance, BODE index, handgrip strength, exacerbations, major cardiovascular events, cancer incidence and renal dysfunction. CONCLUSIONS: AMICO is the first randomized trial specifically designed to evaluate metformin as a gerotherapeutic and disease-modifying intervention in COPD. The study may provide novel evidence supporting geroscience-based approaches to slow disease progression and improve long-term outcomes in patients with COPD.

Why this matters

[human-rct — trial design only] AMICO extends metformin’s geroscience testing to COPD, evaluating lung function decline and age-related comorbidities over 36 months. The design report adds a planned clinical test, not evidence that metformin slows biological aging or improves COPD outcomes; phase III status does not establish efficacy.

Source

Link

Briefing card

Targeting Accelerated Aging in COPD: The AMICO (A Trial of Metformin In COpd) Trial Design.
Stage: trial late · pubmed · 04-nov-2026

If you have COPD, this report describes a trial of metformin, not results showing that it preserves lung function or reduces age-related comorbidities.

The phase III AMICO trial evaluates whether 36 months of metformin (850 mg twice daily) can act as a gerotherapeutic to slow lung function decline and reduce age-related comorbidities in COPD.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1080/15412555.2026.2753977

build build 880 · 2bcef25 · 2026-11-18